Best Chemotherapy for uterine cancer Doctors Worldwide — TOP 52

Dr. Bulent Karagoz is a medical oncologist at Anadolu Medical Center in Istanbul. He specializes in immunotherapy and targeted therapies for sarcoma, lymphoma, and lung cancer. Dr. Karagoz provides treatment at a facility affiliated with the prestigious Johns Hopkins Hospital.

• Authored over 40 research publications focusing on tumor biology and immunology.
• Former Head of Internal Diseases at Istanbul Okan University Faculty of Medicine.
• Held leadership roles in medical oncology at GATA Haydarpasa Training Hospital.
• Member of the Turkish Medical Oncology Association and European Head and Neck Society.

Prof. Merimsky is a leading expert in oncology with extensive experience in uterine cancer chemotherapy at Sourasky Medical Center (Ichilov).

• Over 41 years specializing in oncology, with a focus on gynecologic cancers
• Associate Professor at Sackler Faculty of Medicine, training future oncologists
• Member of the European Society of Medical Oncology (ESMO) Sarcoma Faculty
• Fellowship training in soft tissue and bone oncology at Institut Gustave Roussy, Paris
• Vice Chairman of the Ethical Committee at Sourasky Medical Center

Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.

Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.

Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.

Dr. He Weibing is a pioneer of argon-helium cryoablation in China with more than 20 years of frontline practice. He was a founding member of Fuda Cancer Hospital (Guangzhou). He co-founded its Minimally Invasive Tumor Treatment Center and served as Executive Deputy Director. He also helped found the Ablation Group of the China Anti-Cancer Association. He has been the primary operator in more than 10,000 procedures.

He specializes in tumor cryoablation and is proficient in 125I seed brachytherapy, with a focus on liver and lung cancers. He proposed ten argon-helium techniques. Key co-authored data include: lung cryotherapy n=508; NSCLC n=120 (CR 25.5%, PR 41.8%, 6/12/24-month survival 64%/55%/36%); pancreatic cancer n=38 (median survival 12 months). He served on editorial boards in 2008 and 2010. He has been a national trainer for Varian and Boston Scientific since 2001.

Professor Luo Xiaoping is a nationally recognized interventional radiologist and a leading authority in Western China. He began pioneering vascular interventions in the early 1990s. He helped found the Interventional Group at the Second Affiliated Hospital of Chongqing Medical University.

He has completed over 100,000 interventional procedures, including about 4,000 complex cases. His key skills include TACE for hepatocellular carcinoma, Budd–Chiari interventions, TIPS, and single-stage bilateral stenting for hilar biliary obstruction, with success rates near 100%. He has been a master’s supervisor since 2007. He has trained many physicians, guided complex cases at more than 40 major hospitals across Western China, and helped build interventional programs. He has published 32 papers as first or corresponding author (22 CSCD core, 4 Chinese core, 6 CSCD extended).

Prof. Sezer Sağlam specializes in medical oncology with a focus on uterine cancer treatment at Gayrettepe Florence Nightingale Hospital.

• Professor of Medical Oncology since 2016
• Fellowship-trained at Istanbul University Medical Faculty
• Member of ESMO, ASCO, and Turkish Medical Oncology Association
• Extensive experience in gastrointestinal oncology

Dr. Osama Abdel Mohimen Mohamed leads the Hematology Unit at Shefaa Al Orman Oncology Hospital. He treats complex blood cancers, including leukemia, lymphoma, and myeloma. Dr. Mohamed is a member of the European Society for Medical Oncology. He also holds memberships in the American Society of Hematology and ASBMT.

• Specializes in chemotherapy, immunotherapy, and bone marrow transplantation.
• Manages aggressive acute leukemia and chronic blood disorders.
• Treats complications arising from various solid tumors.
• Works at an ESMO-accredited center that handles 6,000 patients annually.

Professor Xiao Yueyong is Chief Physician in the Department of Radiological Diagnosis at the Chinese PLA General Hospital. He is a leading expert in minimally invasive interventional oncology. He serves as the inaugural President of WATA (2025–). He is President of the International (2020–) and Asian (2012–) Societies of Cryotherapy. He is also Deputy Head of the NHC Expert Group on tumour ablation regulations (2009–).

He has performed over 100,000 CT/MRI‑guided minimally invasive procedures. His work covers chemical ablation, RFA, MWA, cryoablation, and NanoKnife (IRE). He introduced and advanced NanoKnife ablation in China. He led the first national standards for tumour cryoablation and NanoKnife.

Honors include the National Special Contribution Award (Lifetime Honorary). He received First Prize from the Chinese Medicine Education Association (2021). He received two Second Prizes for Military Medical Achievements (2016, 2018) and two Second Prizes from the China Anti‑Cancer Association (2019, 2022). He was named Asian Ablation Master. His research record includes 13 Chinese patents. He is the principal investigator for four NSFC projects and one MOST subject. He has published over 200 papers, with over 110 as first or corresponding author and over 40 in SCI journals. He has led over 10 ablation guidelines or consensus statements.

Dr. Sinan Karaaslan is a medical oncologist at Anadolu Medical Center in Istanbul. He specializes in treating breast, colorectal, and urogenital system cancers. Dr. Karaaslan brings clinical expertise from major institutions, including Medical Park and Gülhane Military Medical Academy. He works at a hospital affiliated with the Johns Hopkins Hospital.

• Holds personal certification from the European Society for Medical Oncology.
• Treats complex conditions, including stage 4 colon and lung cancers.
• Member of the Turkish Medical Oncology and Turkish Lung Cancer societies.
• Performs systemic therapies such as immunotherapy, targeted therapy, and chemotherapy.

Dr. Mustafa Solak specializes in gynecologic cancers, including uterine cancer, with training from Hacettepe University Cancer Institute and MD Anderson Cancer Center.

• Completed fellowship at Hacettepe University – Turkey's leading cancer institute
• Trained at MD Anderson – ranked #1 US cancer hospital
• Handles complex cases of reproductive system cancers
• Specializes in both chemotherapy and multimodal approaches

Professor Yesim Yildirim specializes in cancer immunotherapy and targeted therapies, with over 80 international publications and co-authorship in leading oncology handbooks.

• Member of the European Society of Medical Oncology (ESMO)
• Professor at Halic University, Istanbul, with extensive academic credentials
• Specializes in breast, gastrointestinal, and lung cancers
• Completed advanced oncology training at Rambam Medical Centre in Israel

Dr. Seref Komurcu is a medical oncologist at Anadolu Medical Center in Istanbul. He specializes in treating breast, lung, colorectal, and solid cancers. Dr. Komurcu holds both ECFMG and ESMO certifications. He previously served as a professor at Gülhane Military Medical Academy.

• Published over 110 scientific papers on cancer management.
• Provides immunotherapy, targeted therapy, and chemotherapy treatments.
• Member of the American Society of Clinical Oncology.
• Works at a clinic affiliated with Johns Hopkins Medicine.

Dr. Eda Tanrikulu is a clinical oncologist at Anadolu Medical Center in Istanbul. She ranked 3rd nationally in Turkey's minor specialty medical exam. Dr. Tanrikulu specializes in chemotherapy and individualized cancer treatments. She works at a facility affiliated with the Johns Hopkins Hospital.

• Served as the head of the medical oncology unit at Haydarpaşa Numune Hospital.
• Participated in global training at Oxford University and ESMO in Manchester.
• Treats gastrointestinal, urological, lung, and breast cancers.
• Member of the American and European Societies of Medical Oncology.

Dr. Necdet Uskent is a medical oncologist and hematologist at Anadolu Medical Center in Istanbul. He was part of the pioneering team that performed Turkey's first bone marrow transplant. Dr. Uskent holds the European Medical Oncology Certificate and focuses on breast, lung, and gastrointestinal cancers. He works at a facility affiliated with Johns Hopkins Medicine.

• Founder of the Turkish Oncology Group (TOG).
• A founding member of the Turkish Society of Medical Oncology.
• Served as a visiting lecturer at Royal Free and University College Hospital in London.
• Treats complex hematological conditions including lymphomas and myeloma.

The doctor is a highly qualified medical oncologist specializing in breast cancer across all clinical stages, including curative and palliative care. With a medical degree from the Pontificia Universidad Católica del Ecuador and a five-year residency at Hospital de la Santa Creu i Sant Pau, the doctor holds a Master's Degree in Medical Oncology from the Spanish Society of Medical Oncology (SEOM).

Currently practicing at the International Breast Cancer Center (IBCC) and IOB Institute of Oncology Barcelona, the doctor has extensive experience in Phase I clinical trials and research. Clinical expertise extends to neuroendocrine tumors, gynecological cancers, and immunotherapy for non-small cell lung cancer. The doctor is an active member of SEOM and ESMO.

Professor of Medical Oncology with 29 years of experience – Dr. Saglam specializes in gastrointestinal oncology at Florence Nightingale Hospital.

• Fellowship-trained at Istanbul University Oncology Institute
• Member of ESMO, ASCO, and European Neuroendocrine Tumor Society
• Attending physician in Gastrointestinal Oncology since 2005

Specialist in Oncological Gynecology and Radiotherapy at Sourasky Medical Center (Ichilov), focusing on uterine cancer treatment.

• Expertise in both chemotherapy and radiotherapy for gynecological cancers
• Works at a leading medical center in Israel
• Dedicated to personalized treatment plans for uterine cancer

Director of oncology hospitalization at Tel Aviv Medical Center – Dr. Stepfansky leads chemotherapy treatments with precision and care.

• Over 26 years specializing in oncology
• Conducts primary research in phase 1-3 clinical studies
• Trained at Ichilov, one of Israel's leading hospitals
• Experienced in both internal medicine and oncology

Chief Physician at a certified interdisciplinary cancer center – Phd Viola Fox leads innovative treatment development for uterine cancer at BKZ Solingen.

• Specialized in chemotherapy, immunotherapy, and targeted therapy
• Active in molecular biology research for haemato-oncological diseases
• Qualified as a specialist in genetics since 2016
• Member of German and American cancer research societies

Associate Professor Tahsin Ozatli specializes in breast, lung, and gastrointestinal cancers at Istinye Liv University Hospital.

• 2016 years of experience in oncology
• Trained at Selcuk University's Faculty of Medicine
• Worked at Ankara Oncology Clinic and Erzurum Regional Training Hospital
• Promoted to Associate Professor in 2016